Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Business

New Chiefs Named At Biogen, Exelixis

by Michael McCoy
July 5, 2010 | A version of this story appeared in Volume 88, Issue 27
Advertisement

Most Popular in Business

Biogen Idec has appointed George A. Scangos, 62, as CEO, effective July 15. A biologist by training, he joins Biogen from Exelixis, where he has been CEO since 1996. Exelixis, meanwhile, has named Michael Morrissey as its new president and CEO, also effective July 15. Morrissey, a Ph.D. chemist, is currently the firm’s president of R&D. Both companies have had their share of trouble recently. Biogen’s former CEO, James C. Mullen, retired last month after a protracted fight with corporate raider Carl Icahn. And Exelixis just lost its second development partner, Bristol-Myers Squibb, for XL184, the most advanced product in its pipeline.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society

You might also like...

Jay Bradner joins Amgen as R&D head
Serving the chemical, life science, and laboratory worlds
Bayer taps Roche for new CEO
Serving the chemical, life science, and laboratory worlds
Bristol-Myers Names New Chief Executive

Article:

This article has been sent to the following recipient:

2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE